How it works:
Sunitinib is a multi-kinase inhibitor that blocks multiple receptor tyrosine kinases involved in tumour cell proliferation and angiogenesis. It disrupts tumour blood supply, inhibits growth, and induces regression.
Recommended for:
Adults with advanced or metastatic renal cell carcinoma
Patients with gastrointestinal stromal tumours (GIST) resistant to imatinib
Individuals with well-differentiated pancreatic neuroendocrine tumours
Use under the supervision of an oncologist only
Renal cell carcinoma
Gastrointestinal stromal tumours (GIST)
Pancreatic neuroendocrine tumours
SUTINAT is taken orally once daily, typically for 4 weeks followed by a 2-week rest period. Capsules should be swallowed whole with sufficient water. Dosage regimen and treatment duration are determined individually by the physician.
Hypersensitivity to sunitinib or excipients
Pregnancy and breastfeeding
Severe cardiovascular disorders
Uncontrolled hypertension
Fatigue
Nausea, diarrhoea, taste disturbances
Skin rash, skin discolouration
Elevated blood pressure
Hypothyroidism
Leukopenia, thrombocytopenia
Liver function abnormalities
